Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients

  • days left to enroll
  • participants needed
  • sponsor
    Medical University of Vienna
Updated on 4 October 2022


This is a prospective randomised trial investigating the effect of a preemptive administration of levosimendan on postoperative cardiac NT-proBNP concentrations.


Major cardiovascular complications occur in about 3 % of all patients undergoing noncardiac surgery and are even higher in patients with increased preoperative risk factors. N-terminal pro brain natriuretic peptide (NT-proBNP) increases in over two third of patients undergoing surgery and is a strong predictor for perioperative myocardial complications. Levosimendan is a positive inotropic Ca2+ sensitizer and significantly reduces postoperative BNP concentration in cardiac surgery. The evidence in the non-cardiac surgery setting, however, is weak. Therefore, we will test our primary hypothesis that the perioperative administration of levosimendan significantly will reduce postoperative NT-proBNP concentrations in patients undergoing moderate- to high-risk non-cardiac surgery. We will also test the secondary hypotheses that levosimendan will reduce postoperative maximum troponin T (maxTnT) concentration, the incidence of myocardial injury after noncardiac surgery (MINS), myocardial infarction and death within 30 days and one year after surgery.

Condition Cardiovascular Risk Factor
Treatment Placebo, Levosimendan
Clinical Study IdentifierNCT04329624
SponsorMedical University of Vienna
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

All patients need to meet all of the following criteria for inclusion (1-4)
Undergoing major surgery planned for more than 2 hours
65 years of age and 85 years of age
Provide written informed consent AND
Fulfill 2 of the following criteria (A-E)
NT-proBNP 200 ng/L
History of coronary artery disease defined as 1 of the following 7 criteria (I to VII)
I) History of angina
II) History of myocardial infarction or acute coronary syndrome
III) History of a segmental cardiac wall motion abnormality on echocardiography/radionuclide imaging
IV) History of positive myocardial stress test (echocardiographic or radionuclide)
V) History of a coronary artery stenosis > 50%
VI) ECG with pathological Q waves in any two contiguous leads
VII) History of previous artery revascularizations
History of permanent/paroxysmal atrial fibrillation diagnosed by physician/specialist
History of peripheral arterial disease as defined by a physician/specialist diagnosis of a current, or prior history of any 1 of the following 5criteria (I-V)
I) Intermittent claudication
II) Stenosis 70 % detected by angiography or doppler
III) Stenosis 70% detected by angiography or doppler AND requiring medical treatment e.g. ASA or other platelet inhibitor
IV) History of stroke or TIA - diagnosed by physician or CT/MRI
V) Diagnosed cerebral arteriovascular disease (cAVK) diagnosed by a physician/specialist
Any 3 of 10 of the following risk criteria (i - x)
i. History of congestive heart failure defined as a physician diagnosis of a current or prior episode of congestive heart failure OR prior radiographic evidence of vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary edema
ii. History of a transient ischemic attack
iii. Diabetes and currently taking an oral hypoglycemic agent or insulin
iv. History of hypertension
v. Hyperlipidemia and currently taking a lipid lowering agent
vi. Documented chronic kidney disease diagnosed by physician/specialist and creatinine clearance > 30 ml/min
vii. History of smoking within 2 years of surgery
viii. Diastolic dysfunction ( grade 1) documented by echocardiography
ix. Age 70 years
x. Preoperative Troponin T (5th generation) 25ng/dL

Exclusion Criteria

Previous adverse response and/or allergy to levosimendan B) ICU Patients undergoing surgery C) Preoperative Sepsis/SIRS needing ICU treatment D) Preoperative hemodynamically instable patients, who requirevasopressor or inotropic support E) Renal or liver transplantation F) History of severe heart failure (e.g. LVEF < 30%) G) Patients undergoing surgery for pheochromocytoma H) Liver cirrhosis I) Pulmonary hypertension (mPAP > 25 mmHg)
Severe Renal Failure defines as creatinine clearance 30ml/min
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note